- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00499460
Effects of Garlic Supplements on Opioids in Healthy Volunteers
Modulation of Opioid Effects by Garlic Supplements
RATIONALE: Garlic supplements may alter the pharmacokinetics of oxycodone, thereby affecting its effectiveness as an opioid analgesic for the relief of moderate or severe pain.
PURPOSE: This randomized phase 4 trial is studying how garlic supplements may change the pharmacokinetics of oxycodone and its analgesic and side effects in healthy volunteers.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
- To determine whether CYP3A (Cytochrome P450 3A) and/or P-glycoprotein mediated interactions exist between garlic supplements and oxycodone (a commonly used oral opioid analgesic) in healthy volunteers.
OUTLINE:
This is a single-blind, randomized, crossover study. Participants are randomized to 1 of 2 arms. Each arm entails two 30-day treatment periods, with a washout of at least 4 weeks in between.
- Arm I: In Period 1, participants receive oral garlic powder twice daily on days 1-28 and oral oxycodone on day 28. In Period 2, participants receive oral placebo twice daily on days 1-28 and oral oxycodone on day 28.
- Arm II: In Period 1, participants receive oral placebo twice daily on days 1-28 and oral oxycodone on days 28. In Period 2, participants receive oral garlic powder twice daily on days 1-28 and oral oxycodone on day 28.
In both periods of each arm, participants receive a combination of oral midazolam and oral digoxin for CYP3A and P-glycoprotein phenotyping on day 29. Blood samples are collected periodically and analyzed by liquid chromatography-mass spectrometry (LC-MS).
Blood and urine samples are collected after receiving oxycodone for pharmacokinetic characterization. Plasma concentrations of oxycodone and its metabolites are measured by LC-MS.
Response to experimentally induced pain by the Cold Pressor Test (CPT) is assessed at baseline and periodically after oxycodone treatment. Subjective ratings of opioid side effects are assessed by validated questionnaires for somatic side effects and cognitive function impairments.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98109-1024
- Fred Hutchinson Cancer Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
- Healthy volunteer
- Body mass index 20-32
EXCLUSION CRITERIA:
- Not pregnant
- No history of cardiopulmonary, liver, renal, endocrine, neurologic, or psychiatric disease
- No anemia
- No known adverse reactions to opioids, benzodiazepines, cardiac glycosides, or garlic supplements
- No known allergy or hypersensitivity to sulfur-containing food or drugs
- No significant gastrointestinal intolerance to lactose in dairy products
- No recent history of alcohol or substance abuse
- No history of or concurrent heavy daily consumption of allium vegetables (i.e., garlic, shallots, leeks, and chives)
- No handicaps due to visual and hearing impairments
- No resting heart rate < 50 beats per minutes
- No abnormal cardiac rhythm by EKG
- No unusually sensitive response or resistance to pain stimulation (Cold Pressor Test)
- Must be right handed
- No color blindness
- No history of learning disabilities or dyslexia
- Must be literate and proficient in English
- Must be a nonsmoker
- No concurrent medication except oral contraceptives
- No concurrent grapefruit or grapefruit juice
- No other concurrent over-the-counter herbal products or herbal tea
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Arm I
Two 30-day treatment periods separated by a washout of at least 4 weeks.
In Period 1, participants receive oral garlic powder tablet twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
In Period 2, participants receive oral placebo twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
|
Each Garlicin tablet has a claimed allicin content of 3,200 microgram per tablet
Other Names:
Single administration of three 5-mg oxycodone tablets or a 15-mg dose
Other Names:
|
OTHER: Arm II
Two 30-day treatment periods separated by a washout of at least 4 weeks.
In Period 1, participants receive oral placebo twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
In Period 2, participants receive oral garlic powder tablet twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
|
Each Garlicin tablet has a claimed allicin content of 3,200 microgram per tablet
Other Names:
Single administration of three 5-mg oxycodone tablets or a 15-mg dose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oxycodone Oral Clearance
Time Frame: Serial blood sampling over 24 hours after a 15-mg oral dose of oxycodone
|
Oxycodone oral clearance is computed by Dose/AUC, where AUC is the area under the plasma oxycodone concentration-time curve from time zero to infinity.
Oral clearance is a measure of the rate at which oxycodone is cleared from the body via metabolism.
|
Serial blood sampling over 24 hours after a 15-mg oral dose of oxycodone
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cold Pressor Tolerance AUC
Time Frame: Repeated testing for tolerance to Cold Pressor Test just before and at 45, 90, 150 and 300 min after a single 15-mg oral dose of oxycodone
|
Cold Pressor Test measures response to experimentally induced pain, in this case by immersion of a subject's hand in icy-cold water.
Tolerance is the duration of time a subject is able to keep his/her hand immersed in the cold water.
A prolongation in tolerance time indicates analgesic response to oxycodone treatment.
Cold Pressor Tolerance AUC is the area under the tolerance versus time curve over a 300-min period after a test dose of oxycodone.
Because of non-normality in sample distribution, log transformed AUC estimates were analyzed by Generalized Linear Model.
|
Repeated testing for tolerance to Cold Pressor Test just before and at 45, 90, 150 and 300 min after a single 15-mg oral dose of oxycodone
|
Somatic Side Effects Total Score
Time Frame: SSE scores at 150 min after a single 15-mg oral dose of oxycodone
|
Subjects rated the bodily side effects they experienced at 90, 150 and 300 min after oxycodone administration on a 35-item Somatic Side Effects (SSE) questionnaire.
Total score (i.e., average of the scores for all 35 items) ranges on a numerical scale from 0 (no somatic side effects) to a maximum of 4 (extreme somatic aide effects).
Only the peak SSE scores at 150 min are reported herein.
|
SSE scores at 150 min after a single 15-mg oral dose of oxycodone
|
Cognitive-Affective Side Effects Total Score
Time Frame: CASE scores at 150 min after a single 15-mg oral dose of oxycodone
|
Subjects rated the mental side effects they experienced at 90, 150 and 300 min after oxycodone administration on a 36-item Cognitive-Affective Side Effects (CASE) questionnaire.
Total score (i.e., average of the scores for all 36 items) ranges on a numerical scale from 0 (no somatic side effects) to a maximum of 4 (extreme somatic aide effects).
Only the peak CASE scores at 150 min are reported herein.
|
CASE scores at 150 min after a single 15-mg oral dose of oxycodone
|
Oral Midazolam Test
Time Frame: Serial blood sampling over 6 hours after a 5-mg oral test dose of midazolam
|
Midazolam when given orally is a probe substrate for the in vivo intestinal and hepatic activity of CYP3A (Cytochrome P450 3A) enzymes.
The phenotype index in this case is the area under the plasma midazolam concentration from time zero to 360 min after a 5-mg oral test dose.
A decrease in oral midazolam AUC indicates enhanced activity of CYP3A enzymes, possibly as a result of enzyme induction.
|
Serial blood sampling over 6 hours after a 5-mg oral test dose of midazolam
|
Oral Digoxin Test
Time Frame: Serial blood sampling over 4 hours after a 0.5-mg oral test dose of digoxin
|
Digoxin when given orally is a probe substrate for the efflux activity of P-glycoprotein in the small intestine.
The phenotype index in this case is the area under the plasma digoxin concentration from time zero to 240 min after a 0.5-mg oral test dose.
A decrease in oral digoxin AUC indicates an enhanced activity of P-glycoprotein, possibly as a result of transporter upregulation.
|
Serial blood sampling over 4 hours after a 0.5-mg oral test dose of digoxin
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Danny D Shen, PhD, Fred Hutchinson Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2040.00
- IR-6130 (OTHER: FHCRC IRB)
- CDR0000551927 (OTHER: PDQ)
- R21CA118334 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy, No Evidence of Disease
-
National Cancer Institute (NCI)CompletedHealthy, no Evidence of DiseaseUnited States
-
Cancer Research UKUnknownHealthy, no Evidence of DiseaseUnited Kingdom
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedHealthy, no Evidence of DiseaseUnited States
-
National Cancer Institute (NCI)CompletedHealthy, no Evidence of DiseaseUnited States
-
National Cancer Institute (NCI)TerminatedHealthy, no Evidence of DiseaseUnited States
-
National Cancer Institute (NCI)CompletedHealthy, no Evidence of DiseaseUnited States
-
National Cancer Institute (NCI)CompletedHealthy, no Evidence of DiseaseUnited States
-
National Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)Completed
Clinical Trials on garlic powder tablets
-
Institute for Atherosclerosis Research, RussiaCompletedCarotid AtherosclerosisRussian Federation
-
Chonbuk National University HospitalCompletedHyperlipidemiaKorea, Republic of
-
National Center for Complementary and Integrative...CompletedArteriosclerosis | Intracranial ArteriosclerosisUnited States
-
Silliker, Inc.National Center for Complementary and Integrative Health (NCCIH)Unknown
-
Fred Hutchinson Cancer CenterNational Center for Complementary and Integrative Health (NCCIH)Completed
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
National Center for Complementary and Integrative...Office of Dietary Supplements (ODS)Completed
-
The Hospital for Sick ChildrenInternational Centre for Diarrhoeal Disease Research, Bangladesh; The Sprinkles...Completed
-
Institute for Atherosclerosis Research, RussiaNot yet recruitingPeripheral Arterial Disease | AtherosclerosisRussian Federation
-
Institute for Atherosclerosis Research, RussiaRecruitingMyocardial Ischemia | Coronary Arteriosclerosis | Coronary Artery Bypass Grafting | Percutaneous Coronary RevascularizationRussian Federation